Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved ...

The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...

Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.

Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year ...

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...

EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis: North Chicago, Illinois Monday, March 3, 2025, 15:00 Hrs [IST] AbbVie annou ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...

Basel: Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

EMA committee recommends marketing approval for Novartis oral Fabhalta to treat adults living with C3 glomerulopathy: Basel Monday, March 3, 2025, 10:00 Hrs [IST] Novartis announc ...